Navigation Links
Endo Pharmaceuticals to Announce Second Quarter 2011 Financial Results on August 9, 2011
Date:7/26/2011

CHADDS FORD, Pa., July 26, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it will host a conference call and live Internet webcast on Tuesday, August 9, 2011 at 8:30 a.m. ET to discuss results for the 2011 second quarter.  

David P. Holveck, president and CEO, Julie McHugh, chief operating officer, Dr. Ivan Gergel, executive vice president of R&D, Alan Levin, executive vice president and chief financial officer, Tony Bihl, group president, American Medical Systems, and Blaine Davis, vice president, corporate affairs will host the call.

Investors and other interested parties may call 866-203-2528 (domestic) or 617-213-8847 (international) and enter passcode 76257989.  Please dial in 10 minutes prior to the scheduled start time.

A replay of the call will be available from August 9, 2011 at 12:30 p.m. ET until 12:00 p.m. ET on August 23, 2011 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and entering passcode 82161745.

A simultaneous webcast of the call may be accessed by visiting www.endo.com.  In addition, a replay of the webcast will be available until 12:00 p.m. ET on August 23, 2011.  The replay can be accessed by clicking on "Events" in the Investor Relations section of the website.

About Endo

Endo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company, focused on high-value branded products and specialty generics. Endo is redefining its position in the healthcare marketplace by anticipating and embracing the evolution of health decisions based on the need for high-quality and cost-effective care. We aim to be the premier partner to healthcare professionals and payment providers, delivering an innovative suite of complementary diagnostics, drugs, devices and clinical data to meet the needs of patients in areas such as pain, urology, oncology and endocrinology. For more information about Endo Pharmaceuticals, and its wholly owned subsidiaries American Medical Systems, Inc., HealthTronics, Inc. and Qualitest Pharmaceuticals, please visit http://www.endo.com/.


'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... -- According to a new market research ... by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), by Application (Drug ... Hospitals/ Clinics) - Forecast to 2021", published by MarketsandMarkets, ... the forecast period of 2016 to 2021. This market ... from USD 117.3 Million in 2016, at a CAGR ...
(Date:5/25/2016)... 25, 2016  Zymo Research Corp. announced today ... reference materials that help researchers obtain the most ... analyses. The rapid growth of the study of ... have standard methods to improve the reproducibility and ... exist at every step of the measurement process ...
(Date:5/25/2016)... As illustrated by the Spring ... the numbers and momentum of cannabis in the US ... billions, more research and development push the sector forward. ... Legal Marijuana Markets Report  from from ArcView Market Research ... the increase in sector is attributed to adult use ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... According to the Webster’s dictionary, a hippie ... chemical-laden beauty products, one company is going against the norm with a line of ... rising star in the green space is proud to announce its latest retail partnership ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... HealthPostures, ergonomics ... Angle chair , furniture that may support women during pregnancy. Potential benefits of using ... feet, improved rest and comfort and healthier levels of sitting and standing. , Need ...
(Date:5/25/2016)... ... ... The United States Food and Drug Administration (FDA) has now cleared Capillus® ... date, the company is the first and only manufacturer of low level laser therapy ... alopecia. , “This new level of clearance substantiates what many physicians have experienced ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... a Managing Partner at HealthScape Advisors. “Brad brings significant experience advising healthcare provider ... delivery system accelerates with the implementation of MACRA, we believe that continuing to ...
(Date:5/25/2016)... , ... May 25, 2016 , ... Furthering its position ... athletics, The National Center for Drug Free Sport (Drug Free Sport®) is excited to ... conference, to be held July 12 – 13 in Kansas City, MO, will gather ...
Breaking Medicine News(10 mins):